GlassScriptPhysician profile
Bradley Tymchuk
NPI 1437503380
$1,417.50
in general payments reported to CMS, 2019-2025
22 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $372 · 2022: $55.34 · 2023: $234 · 2024: $266 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.99 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $154.32 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $148.24 | 2019-2025 | Breztri |
| Amgen INC. | $131.38 | 2020 | |
| Novo Nordisk INC | $117.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $101.27 | 2023-2025 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $82.92 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.72 | 2023-2024 | |
| Lilly USA, LLC | $48.97 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $46.75 | 2025 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.97 | 2025 | Relistor |
| Xeris Pharmaceuticals, INC. | $35.48 | 2023-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $34.32 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $32.28 | 2019-2024 | |
| Medtronic, INC. | $30.88 | 2025 | Minimed 780g |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $29.68 | 2020-2023 | Yupelri |
| Alexion Pharmaceuticals, INC. | $27.88 | 2025 | Strensiq |
| Sumitomo Pharma America, INC. | $26.54 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $19.90 | 2022 | |
| Pfizer INC. | $19.39 | 2024 | |
| Astellas Pharma US INC | $18.70 | 2024 | Veozah |
| Corcept Therapeutics | $16.00 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Tymchuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.